CN102260271B - Cytochalasin compound as well as preparation method thereof and purpose - Google Patents

Cytochalasin compound as well as preparation method thereof and purpose Download PDF

Info

Publication number
CN102260271B
CN102260271B CN 201110153240 CN201110153240A CN102260271B CN 102260271 B CN102260271 B CN 102260271B CN 201110153240 CN201110153240 CN 201110153240 CN 201110153240 A CN201110153240 A CN 201110153240A CN 102260271 B CN102260271 B CN 102260271B
Authority
CN
China
Prior art keywords
compound
preparation
cell
zhn1
chloroform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN 201110153240
Other languages
Chinese (zh)
Other versions
CN102260271A (en
Inventor
李德海
周会楠
朱天骄
顾谦群
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocean University of China
Original Assignee
Ocean University of China
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocean University of China filed Critical Ocean University of China
Priority to CN 201110153240 priority Critical patent/CN102260271B/en
Publication of CN102260271A publication Critical patent/CN102260271A/en
Application granted granted Critical
Publication of CN102260271B publication Critical patent/CN102260271B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to a preparation method and a purpose of a cytochalasin compound. According to the invention, a novel cytochalasin compound is produced by using Aspergillus flavipes ZHN1-09 in a Guangxi mangrove forest plant Cerbera manghas root mug sample. It is proved by experiments that the compound can be used as cell proliferation inhibitors or antitumor agents.

Description

Cytochalasin compounds and its production and use
Technical field:
The present invention relates to that ((on March 24th, 2011 was deposited in Wuhan University Chinese Typical Representative culture collection center, and deposit number is: the method for CCTCC M 2011069) producing the cytochalasin compounds with yellow bright aspergillus ZHN1-09 (Aspergillus flavipes ZHN1-09); The invention still further relates to the purposes of this compounds in preparation inhibition of cell proliferation or antineoplastic agent.
Background technology:
Cytochalasin is the relevant secondary metabolite of a kind of structure and activity of being produced by fungi, and scientists finds that this compounds has many unusual and interesting effects to cell.Inventor's research is learnt, (deposit number is: CCTCC M 2011069) crude extract of liquid fermentation production after ultrasonication has good cell inhibitory effect active to yellow bright aspergillus ZHN1-09 (Aspergillus flavipes ZHN1-09), then its activeconstituents is studied.Compound had anti-tumor activity shown in research was found, had not yet to see the report of chemical structure and the cell inhibitory effect activity of this compound, so also there is not yet relevant therewith medicine on the market.
Summary of the invention:
The present invention aims to provide one and has inhibition tumor cell propagation, has the new compound of anti-tumor activity.Its structural formula is
Figure DEST_PATH_GSB00000621322700011
Its constitutional features is: this compound is the cytochalasin of new ring-type.
Compound of the present invention can cultivate to obtain the fermented product that is rich in the cytochalasin compounds by microbial fermentation, then adopts the method separation and purification such as silica gel column chromatography, Sephadex LH-20 gel filtration chromatography, RP-18 reversed-phase silica gel column chromatography and half preparative HPLC to obtain from fermented product.
Enumerated among the following embodiment of the present invention utilize yellow bright aspergillus ZHN1-09 (Aspergillus flavipes ZHN1-09) (deposit number is: CCTCC M 2011069) preparation the compounds of this invention example.
Embodiment:
The chemical structure of the compound of indication in following embodiment (Arabic numerals in the structural formula are marks of carbon atom in the chemical structure) is:
Figure BSA00000513952200021
Fermentative production and the separation and purification of embodiment 1 this compound
1 fermentative production
Produce the fermentation culture of bacterium: by the ordinary method of culturing micro-organisms, (deposit number is: CCTCC M 2011069) an amount of to get yellow bright aspergillus ZHN1-09 (Aspergillus flavipesZHN1-09), be inoculated on the PDA solid slant culture base, in 28 degrees centigrade of incubators, cultivated 6 days.
It is an amount of to get 6 days yellow bright aspergillus ZHN1-09 (Aspergillus flavipes) of slant culture, is inoculated into 300mL nutrient solution [substratum composition (grams per liter): glucose 10.0, maltose 20.0, N.F,USP MANNITOL 20.0, monosodium glutamate 10.0, KH is housed 2PO 40.5, MgSO 40.3, yeast extract paste 3.0, Semen Maydis powder 0.3, pH=6.5] the 1000mL Erlenmeyer flask in, leave standstill at 28 ℃ and to cultivate 40 days, obtain mycelium and fermented liquid.
The acquisition of 2 medicinal extract
With gauze with mycelium and separation of fermentative broth.With fermented liquid equal-volume ethyl acetate extraction three times, extraction liquid is evaporated to dried; Bacterial cell disruption with 80% acetone extract 3 times, is evaporated to and does not contain acetone, and the residue water layer is with equal-volume ethyl acetate extraction 3 times, and extraction liquid is evaporated to dried; Merge the extract of thalline and fermented liquid, get crude extract, totally 3.4 grams.
The separation and purification of 3 compounds
After medicinal extract dissolves with the chloroform-methanol mixed solvent, add 100-200 order silica gel (Qingdao Haiyang Chemical Industry Group Corp.'s product) and mix sample, after the removal of solvent under reduced pressure, use silica gel column chromatography, with sherwood oil, sherwood oil-acetone, chloroform, chloroform-methanol are that solvent carries out gradient elution, are divided into 4 cuts (Fr-1, Fr-2, Fr-3 and Fr-4).Fr-2 (20: 1 eluates of chloroform-methanol), successively carry out the LH-20 column chromatography take chloroform-methanol (1: 1) as solvent, again through the RP-18 reversed-phase silica gel column chromatography take methyl alcohol: water (40: 60) carries out wash-out as solvent, finally by partly preparing RPLC preparation (methyl alcohol: water=70: 30) must this compound.
Compound white amorphous solid, [α] 25 D=-5.5 (c 0.1, MeOH), and molecular formula C 28H 33NO 6, HR-ESI-MS m/z:480.2379[M+H] +, calculated value 480.2386.IR?v maxcm -1(KBr):3420,2925,2866,1741,1716,1702,1459,1078,665,573。 1H and 13The C-NMR data see Table 1.
Table 1 compound 1H (600MHz) and 13The NMR data of C (150MHz) in CDCl3 a
Figure BSA00000513952200022
Figure BSA00000513952200031
A) this table signal ownership is based on DEPT, HMQC and HMBC spectrum analysis result.The multiple degree binding molecule amount of carbon signal is determined.
B) numeral and the code name in this hurdle represents respectively 1H- 1In the H COSY spectrum with corresponding line in 1H provides the coincidence signal 1H nuclear.
C) numeral in this hurdle and code name represent respectively in HMBC spectrum with corresponding line in 1H provides the coincidence signal 13C nuclear.
The test of embodiment 2 anti tumor activity in vitro
The cell inhibitory effect active testing
1 laboratory sample and experimental technique
The preparation specimen of sample solution is the pure compounds of separation and purification in above-described embodiment 1.Precision takes by weighing an amount of sample, is mixed with the solution of desired concn with methyl alcohol, and is active for surveying.
The succeeding transfer culture of clone and cell adopts the cancerous cell lines such as people's lung cancer A549 cell, human leukemia HL60 cell and P 388 cells.Various cells are all with the RPMI-1640 substratum that contains 10%FBS, at 37 ℃ of succeeding transfer culture in the incubator that passes into 5% carbonic acid gas.
The cell inhibitory effect activity test method
It is every milliliter 2 * 10 that people's lung cancer A549 cell that Sulforhodamine B (SRB) method is taken the logarithm vegetative period is mixed with density with fresh RPMI-1640 substratum 5The cell suspension of individual cell is inoculated in 96 orifice plates by every hole 200 microlitres, and every hole adds sample or the blank solution of 2 microlitre different concns, 37 ℃ of lower cultivations 24 hours.Get it filled cell after cultivating under the thing effect, the morphological change that at first causes in optical microphotograph Microscopic observation drug treating is judged to have or not the cell cycle to suppress the morphological feature of apoptosis or necrocytosis, then 4 ℃, 3000 rev/mins centrifugal 3 minutes, suck supernatant.Add 20% Tricholroacetic Acid, 50 microlitres in every porocyte, place 4 ℃ to fix 1 hour, water flushing 5 times and dry air.Every hole adds acetum 50 microlitres of 0.4%SRB and left standstill 30 minutes in room temperature.Clean 4 times with 1% acetic acid water, remove unconjugated free SRB dyestuff.Every hole adds 150 microlitre Tris damping fluids (10mmol/L, pH 10.5) soluble protein combination dye and utilizes MD company to produce SPECTRAMAX Plus type microplate reader and measure every hole in optical density(OD) (OD) value at 520nm place.Each concentration of sample all arranges three holes in same 96 orifice plates, and other establishes three hole blanks and acellular zeroing hole (if medicine has color will do the acellular zeroing of relative medicine concentration).Each hole OD value is done first corresponding acellular zeroing, gets the average OD value in three holes by IR%=(OD again Blank-OD Sample)/OD BlankThe X100% formula is calculated the cell proliferation inhibition rate (IR%) under each concentration.
The human leukemia HL60 cell that tetrazolium (MTT) method is taken the logarithm vegetative period and murine leukemia P388 cell transfer to every milliliter 2 * 10 with cell density 5Individual cell is inoculated in the 96 porocyte culture plates by every hole 200 microlitres, passes into 5%CO in 37 ℃ 2Incubator in cultivated 4 hours.Every hole adds each 2 microlitre of sample liquid or blank solution, cultivates after 24 hours, and every hole adds MTT liquid (every milliliter of 5 milligrams of normal saline solutions of MTT) 10 microlitres, continues cultivation 4 hours, 37 ℃, 2000 rev/mins centrifugal 8 minutes, suck supernatant.Every hole adds each 100 microlitre of DMSO, vibrates 15 minutes at micro oscillator, after dissolving fully to crystallization, utilizes MD company to produce SPECTRAMAX Plus type microplate reader and measures every hole at the light absorption value (OD value) at 570nm place.Each concentration of sample all arranges three holes in same 96 orifice plates, and other establishes three hole blanks and acellular zeroing hole (if medicine has color will do the acellular zeroing of relative medicine concentration).Each hole OD value is done first corresponding acellular zeroing, gets the average OD value in three holes by IR%=(OD again Blank-OD Sample)/OD BlankThe X100% formula is calculated the cell proliferation inhibition rate (IR%) under each concentration.
2. experimental result
Cell inhibitory effect active testing result
In srb assay or mtt assay test, this compound of different concns suppresses to the results are shown in Table 2 to the propagation of people's lung cancer A549 cell, human leukemia HL60 cell and P 388 cells.
Table 2 compound is active to the inhibition of different carcinoma cell proliferation
Figure BSA00000513952200041
3 conclusions
This compound has obvious kinds of tumor cells inhibited proliferation, can be used as the research that inhibition of cell proliferation or antineoplastic agent are used for cancer therapy drug.

Claims (5)

1. compound structure is shown below
Figure FSB00001111156900011
2. the preparation method of the described compound of claim 1 is characterized in that the yellow bright aspergillus ZHN1-09 (Aspergillusflavipes, ZHN1-09) of fermentation culture, obtains the fermented product that contains above-claimed cpd, and then separation and purification goes out this compound from fermented product.
3. preparation method claimed in claim 2, wherein with described fermented product through silica gel column chromatography, carry out gradient elution take sherwood oil, sherwood oil-acetone, chloroform, chloroform-methanol as solvent, 20: 1 wash-out parts of chloroform-methanol, through Sephadex LH-20 gel filtration chromatography, RP-18 reversed-phase silica gel column chromatography and half preparative HPLC separation and purification must this compounds again.
4. compound claimed in claim 1 is in the purposes of preparation in the inhibition of cell proliferation.
5. compound claimed in claim 1 is in the purposes of preparation in the antitumor drug.
CN 201110153240 2011-06-01 2011-06-01 Cytochalasin compound as well as preparation method thereof and purpose Expired - Fee Related CN102260271B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 201110153240 CN102260271B (en) 2011-06-01 2011-06-01 Cytochalasin compound as well as preparation method thereof and purpose

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 201110153240 CN102260271B (en) 2011-06-01 2011-06-01 Cytochalasin compound as well as preparation method thereof and purpose

Publications (2)

Publication Number Publication Date
CN102260271A CN102260271A (en) 2011-11-30
CN102260271B true CN102260271B (en) 2013-10-30

Family

ID=45007132

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 201110153240 Expired - Fee Related CN102260271B (en) 2011-06-01 2011-06-01 Cytochalasin compound as well as preparation method thereof and purpose

Country Status (1)

Country Link
CN (1) CN102260271B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103787953B (en) * 2014-01-17 2015-12-02 杭州维康科技有限公司 Compd A spochalasin V and its preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006060A1 (en) * 2001-07-09 2003-01-23 Kyowa Hakko Kogyo Co., Ltd. Sh3 domain binding inhibitors
CN101416962A (en) * 2008-12-05 2009-04-29 中国热带农业科学院热带生物技术研究所 Use of cytochalasin D in preparing anti-tumor medicine
CN101591288A (en) * 2009-06-26 2009-12-02 中国科学院海洋研究所 Cytochalasin compounds and its production and use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006060A1 (en) * 2001-07-09 2003-01-23 Kyowa Hakko Kogyo Co., Ltd. Sh3 domain binding inhibitors
CN101416962A (en) * 2008-12-05 2009-04-29 中国热带农业科学院热带生物技术研究所 Use of cytochalasin D in preparing anti-tumor medicine
CN101591288A (en) * 2009-06-26 2009-12-02 中国科学院海洋研究所 Cytochalasin compounds and its production and use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Takamatsu, S,等.Characterization of Mycotypha metabolites found to be inhibitors of cell adhesion molecules.《JOURNAL OF ANTIBIOTICS 》.2002,第55卷(第6期),第585-592页. *
Tomoda, H,等.Structure elucidation of fungal phenochalasins, novel inhibitors of lipid droplet formation in mouse macrophages.《JOURNAL OF ANTIBIOTICS》.1999,第52卷(第10期),第857-861页. *

Also Published As

Publication number Publication date
CN102260271A (en) 2011-11-30

Similar Documents

Publication Publication Date Title
CN103865808B (en) A kind of anticancer usage of the penicillium sp enol A1 coming from Aspergillus citrimum
CN107298671A (en) Come from the secalonic acid H of penicillium oxalicum and prepare the application of anti-human colon cancer drug
CN107353274A (en) Come from the secalonic acid I of penicillium oxalicum and prepare the application of anti-human oesophagus cancer drug
CN104402899B (en) Citrinin compounds penicitrinol L coming from Aspergillus citrimum and its preparation method and application
CN107298672A (en) The secalonic acid I for coming from penicillium oxalicum is preparing the application of anti-human colon cancer drug
CN101735236B (en) Dimer citrinin compounds and preparation and use thereof
CN107298670A (en) Come from penicillium oxalicum secalonic acid H and prepare anti-human oral cavity epidermoid carcinoma medicinal application
CN101812079B (en) Piprazine compound containing polysulfide bond and preparation method and application thereof
CN107485607A (en) The secalonic acid H for coming from penicillium oxalicum is preparing the application of anti-human oesophagus cancer drug
CN104592082B (en) Come from the penicillium sp enol D of Aspergillus citrimum2preparation method and applications
CN107298669A (en) Come from the secalonic acid I of penicillium oxalicum and anti-human oral cavity epidermoid carcinoma medicinal application
CN104387396B (en) Come from indole terpene speradine E and the application of aspergillus oryzae
CN102260271B (en) Cytochalasin compound as well as preparation method thereof and purpose
CN110407792A (en) Derived from the secalonic acid class compound Secalonic acid J and preparation method of penicillium oxalicum
CN102268005B (en) Indole diketopiperazine alkaloid compound derived from tryptophan and proline and preparation method and application thereof
CN103058846B (en) Benzoquinone derivative from aspergillus aculeatus and application of benzoquinone derivative
CN103030683B (en) Peptaibol and preparation method and use thereof
CN104370917A (en) Indole terpene speradine H derived from aspergillus oryzae and application
CN101735193B (en) 9-anthranone spiro lactone compound and preparation method and application thereof
CN103012559A (en) Peptaibol compound and application thereof
CN103058971B (en) Benzoquinone spiro compound derived from aspergillus aculeatus and application of benzoquinone spiro compound
CN102276613B (en) Sesquiterpene alkaloid compound as well as preparation method and application thereof
CN101735237B (en) Trimeric citrinin compounds as well as preparation methods and applications thereof
CN104211630B (en) A kind of alkaloid compound and application thereof that comes from tangerine green trichoderma
CN105037397A (en) Sulfur-bridge-containing complex-ring-series alkaloids compound, preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131030

Termination date: 20140601